N@N

Vemics Partners with Franklyn Ideas on Pharma Marketing Pact

^{Published on 2009-02-11 05:58:00, Last Modified on 2009-02-11 05:59:06 - Market Wire}
 

NANUET, N.Y.--([ BUSINESS WIRE ])--Vemics, Inc. (OTCBB: VMCI) today announced it has partnered with leading pharmaceutical marketing firm Franklyn Ideas to execute an online communications program designed for use by pharmas utilizing VMCI's iMedicor medical communications portal.

This portal, which will enable real-time online communications between pharmaceutical companies and 700,000 healthcare providers nationwide, allows pharmas to transmit product information in text or video on a 24/7 basis for a fraction of the cost of in-person marketing. Doctors receiving this information may utilize iMedicor to order product samples, set appointments with pharma sales representatives and communicate directly with pharma medical science liaisons.

Franklyn Ideas program for Vemics is designed to maximize the promotional effectiveness of pharmaceutical product information transmitted to healthcare providers through the portal.

One of the marketing agencies behind the launch of Lipitor—one of the world's best selling drugs—Franklyn Ideas currently serves some of the world's largest pharmaceutical companies and has engineered marketing programs for hundreds of brands.

"We look forward to a profitable relationship with Vemics," said Franklyn Ideas principal, Stacey Richter. "There is no doubt that online marketing programs delivered via highly trafficked medical community portals offer pharmaceutical companies multiple advantages—cost and otherwise—which can supplement or possibly supplant in-person and other traditional marketing strategies.

"Working with Vemics, we expect to design programs that are customized to each pharma and each brand's specific needs—and which, we believe, will produce an exceptional response rate from physicians."

Vemics chief executive, Fred Zolla, added, "Today's announcement marks a further step in building what we believe will be among the nation's most effective online medical communications networks. With the input contributed by Franklyn Ideas, pharmaceutical companies utilizing iMedicor will be able to formulate marketing messages proven to elicit the highest rate of success among healthcare providers. We too look forward to engaging in this vital program."

Announcements detailing new pharma subscribers to iMedicor are expected to be made in the near future, said Mr. Zolla.

About Franklyn Ideas

Based in Parsippany, New Jersey, Franklyn Ideas creates marketing programs for many of the largest pharmaceutical companies in the world. The company's scope of services features formulary access materials and messaging platforms, representative-delivered and non-personal communication tactics and tactical plans, package insert and packaging management and website/digital asset maintenance.

About Vemics

Vemics' iMedicor portal enables pharmaceutical companies to deliver customized marketing messages, in a highly targeted, cost-effective and non-intrusive manner, to more than 700,000 healthcare providers nationwide. iMedicor also allows doctors, administrators and other qualified healthcare workers to send and receive HIPAA-compliant medical records, files and images as well as permitting various EMR (electronic medical record) systems to communicate, collaborate and exchange records in real time. Additionally, the portal can deliver the highest quality CME (continuing medical education) programs sponsored by medical societies, pharmaceutical companies, medical device companies and the US Military. iMedicor is based in Austin, Texas. Vemics' corporate offices are located in Nanuet, New York. [ www.vemics.com ], [ www.imedicor.com ].

The statements contained herein, other than historical information, are or may be deemed to be forward-looking statements and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. These factors, risks, and uncertainties include market acceptance of Vemics' products and services; the nonexclusive and terminable-at-will nature of certain of the company's partnerships and agreements; rapid technological change affecting demand for our products and services; competition from companies providing similar products and services, availability of sufficient financial resources to enable us to expand our operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission.